The market for treating sickle cell disease (SCD) is seeing substantial growth, driven by breakthroughs in medical research, growing public understanding, and the rise of new treatments. It is anticipated that since therapies including genetic-based approaches, gene-editing methods, and novel medications in the pipeline address the cause rather than the symptoms of this genetic disease, the market will keep on expanding.
This global growth is further supported by increased healthcare funding, improved diagnostic tools, and the higher prevalence of SCD, especially from sub-Saharan Africa and parts of Asia. In most, if not some, of the near futures, genetic treatments are foreseen to revolutionize the treatment of the disease.
Approaches include gene modification, which can have very positive results and offer further opportunities for long-term or permanent treatments. Approval of medications, including voxelotor and crizanlizumab, improves patient outcomes further and is a plus factor in boosting optimism among prospects of this market.
Future opportunities, however, lie in improving access to care, especially in developing nations where the disease burden is higher. Regarding such challenges, it will be important to develop genetic treatments, affordable oral drugs, and the other advanced therapies.
As healthcare systems improve globally, so will demand for both - preventive measures and ongoing care solutions. Ultimately, the market for SCD treatments is on course to experience considerable growth due to medical innovations, expanding care access, and an increased global focus on managing this chronic condition.
Sickle Cell Disease (SCD) is a genetic blood disorder primarily affecting individuals of African, Mediterranean, Middle Eastern, and Indian origin. It leads to the production of abnormal hemoglobin, causing red blood cells to adopt a crescent or sickle shape. This shape reduces the cells' ability to transport oxygen, leading to symptoms such as severe pain, fatigue, and organ damage.
The global prevalence of SCD is significant, with an estimated 20-25 million people affected worldwide. The highest burden is seen in sub-Saharan Africa, where one in every 100-150 children is born with the disease. In the United States, around 100,000 individuals live with SCD, with the majority being of African American descent. As awareness grows and healthcare access improves in emerging economies, the market for SCD treatments is experiencing robust growth.
The SCD treatment market is expanding as research and development continue to focus on novel therapies. Traditional treatments include pain management, blood transfusions, and hydroxyurea, a drug that helps reduce complications. However, the market is seeing transformative growth with the development of gene therapies, bone marrow transplants, and CRISPR-based interventions.
Companies like Vertex Pharmaceuticals, bluebird bio, and Novartis are at the forefront, with promising therapies like crizanlizumab (a monoclonal antibody) and exagamglogene autotemcel (a gene therapy for SCD). These innovations hold the potential to reduce the frequency of painful crises, improve quality of life, and even offer a potential cure.
Market dynamics are influenced by factors such as increased awareness, advancements in gene therapies, regulatory approvals, and rising healthcare investments. As more novel treatments reach the market, the overall outlook for the SCD treatment landscape appears positive, offering hope to millions of affected individuals worldwide.
| Attribute | Detail |
|---|---|
| Drivers to Sickle Cell Disease Treatment Market |
|
One of the prominent reasons contributing to increased gene therapy adoption in sickle cell disease treatment across the globe is promising advancements in genetic studies, with technologies such as CRISPR-Cas9 gene editing, in particular. Gene therapy targets the cause of the disease person's faulty genes and treats genetic-based conditions, which, when used for conditions such as sickle cell anemia, could mean offering lifetime cures instead of simply controlling their symptoms.
For instance, CRISPR Therapeutics and Vertex Pharmaceuticals run a Phase 3 clinical trial of the gene-edited therapy, CTX001, against sickle cell disease. CTX001 uses CRISPR-Cas9 technology to correct the genetic mutation that causes the disease.
The fact that the clinical trials are expected to be completed by October 2024, with positive results so far, brings hope that this treatment will revolutionize the management of sickle cell disease by offering a cure to the patients instead of lifelong blood transfusions or other forms of continuous treatment. This advancement of gene therapy underlines its transformative impact on hereditary diseases.
Due to the success of CTX001 and the other similar therapies, confidence among providers, patients, and pharmaceutical companies is developing. Due to the efficacy and safety exhibited by these therapies during their clinical trials, pharmaceutical R&D efforts have increasingly focused on the development of gene therapy solutions for diseases such as sickle cell anemia.
Gene therapy has been a game-changer in the landscape of treatment options as it attacks the root of sickle cell disease, not just its symptoms. Hence, such positive clinical results for research will continue to fuel the momentum in the demand within the global sickle cell disease treatment market.
As treatments begin to transition from mere alleviation therapies to more gene-related curative therapies that may offer permanent cures for congenital disorders like sickle cell, companies within the ecosystem are eager to seize the tide of such developing dynamics and are correspondingly seeing an uptake in adoptions to drive demand up over the forecast period.
One of the major factors that have been contributing to the growth in the adoption of gene therapy in the global SCD treatment market: an increase in the prevalence and severity of the disease.
Sickle cell disease burdens millions of people across the globe, and its high prevalence, coupled with the severity of its symptoms, is driving the demand for better treatment options. For example, CDC estimations have marked that the overall number suffering from SCD in the United States closed on 100,000 in May 2022 alone, showing the unimaginative burden of the disease due to it.
The rising cases of sickle cell disease have created an emerging urge for better treatments, fueling the growth prospects. The condition often results in attacks of severe pain that are medically referred to as vaso-occlusive crises or VOCs. According to a study estimated by the NCBI, the average annual occurrence of up to 18 VOCs occur in patients with SCD. These are heavy with frequent painful attacks that add to the high burden on patients and healthcare alike.
This growing incidence and severity of symptoms accelerate the development of new therapies. For example, in November 2019, the FDA granted Pfizer's Oxbryta fast-track approval for adults and children aged 12 years and older. In 2021, the FDA expanded the approval to include children aged 4 years and older.
Oxbryta works by reducing the frequency of VOC and is a big relief for patients. The growing recognition of the disease burden and response to treatments like Oxbryta in lessening the severity of VOCs have been some of the reasons for the growing adoption of such therapies.
Thus, increasing cases and high severity of the disease are some of the key factors that drive growth in the sickle cell disease treatment market, as both patients and healthcare providers want better solutions to manage or alleviate the condition.
By drug class, antimetabolites segment is dominating the global sickle cell disease treatment industry. This can be attributed to better adoption of the segment of antimetabolites with advancements in drug development, heightened awareness, and improvement in diagnosis.
The major factors responsible for the growth of this market include the rising prevalence of SCD, especially in the Sub-Saharan Africa region and some Middle Eastern countries, coupled with higher investments in healthcare. All these factors together propelled the demand for serious and effective treatments, which comprise antimetabolites amongst the front runners owing to their therapeutic benefits.
Hydroxyurea represents one of the most essential drugs from the antimetabolites used in sickle cell disease management. In fact, to many experts, it represents the cornerstone of SCD management. It works by increasing the levels of HbF in red cells, which reduces the frequency of cell sickling and painful crises. The drug showed that it can reduce rates of hospitalization, the rate at which blood transfusion needs to be done, and improve a better quality of life among SCD patients.
The hemoglobin SS (HbSS) segment is projected to dominate the global sickle cell disease treatment market during the forecast period owing to several factors. This leads to the production of abnormal hemoglobin, which causes sickling of the red blood cells, obstruction of blood flow, frequent painful crises, organ damage, and shortened life expectancy. Being serious, HbSS necessitates urgent medical interventions, hence driving the growth in the treatment market.
HbSS is the largest segment in the global market and accounts for approximately 60-80% of all cases of SCD. About 300,000 newborn babies worldwide are diagnosed with sickle cell disease every year, out of which a considerable number are suffering from HbSS, especially from high-prevalence regions such as Sub-Saharan Africa, where SCD remains a major public health challenge.
An approximate 100,000 individuals in the United States alone are documented to be afflicted with sickle cell disease, with approximately 60 to 70% diagnosed with the HbSS type, and that count is prevalently dispersed throughout various geographical spots around the globe, a factor fostering the need for appropriate therapy levels, and further driving forward the SCD global market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
The North American region is expected to dominate the global sickle cell disease treatment market during the forecast period. Growth in the North American market is propelled by increasing awareness of sickle cell disease as a major public health priority, particularly in the United States, where almost 100,000 people live with SCD, the majority being African Americans.
Accordingly, this creates a huge patient population in continuous need of treatment and care: According to the Centers for Disease Control and Prevention, the incidence of SCD is about 1 in 365 African American births and 1 in 16,300 Hispanic American births.
Hydroxyurea, for example, was one of the pioneering oral therapeutic agents for the treatment of SCD and is still extensively prescribed in the U.S. market today, contributing well to the dominant position established by oral therapies.
Novelties in recent years-such as the FDA approvals secured by Voxelotor, also known as Oxbryta, and Crizanlizumab, known as Adakveo- enabling new hope for patients. Even more, gene therapies such as Zynteglo-for which FDA approval may stand as a cure for this disease made North America an undisputable leader within the world treatment landscape.
The leading players in the sickle cell disease treatment market include Bristol-Myers Squibb Company, Novartis AG, Emmaus Medical, Inc., Bluebird bio Inc., Pfizer Inc., CRISPR Therapeutics, F. Hoffmann-La Roche AG, Vertex Pharmaceuticals, Incorporated, Agios Pharmaceuticals, Inc., GlycoMimetics, Graphite Bio, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca, Hikma Pharmaceuticals PLC, Addmedica and Others
Each of these players have been have been profiled in the sickle cell disease treatment market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 2.7 Bn |
| Forecast Value in 2034 | More than US$ 17.7 Bn |
| CAGR | 18.5% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2018-2022 |
| Quantitative Units | US$ Bn for Value |
| Sickle Cell Disease Treatment Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global sickle cell disease treatment market was valued at US$ 2.7 Bn in 2023.
The global sickle cell disease treatment market is projected to cross US$ 17.7 Bn by the end of 2034.
Increasing gene therapy adoption and increasing prevalence along with high severity related to the disease.
The CAGR is anticipated to be 18.5% from 2024 to 2034.
North America is expected to account for the largest share from 2024 to 2034.
Bristol-Myers Squibb Company, Novartis AG, Emmaus Medical, Inc., Bluebird bio Inc., Pfizer Inc., CRISPR Therapeutics, F. Hoffmann-La Roche AG, Vertex Pharmaceuticals, Incorporated, Agios Pharmaceuticals, Inc., GlycoMimetics, Graphite Bio, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca, Hikma Pharmaceuticals PLC, Addmedica and Others.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sickle Cell Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sickle Cell Disease Treatment Market Analysis and Forecast, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events
5.2. PEST Analysis
5.3. Pipeline Analysis
5.4. Regulatory Scenario by Key Countries/Regions
5.5. PORTER’s Five Forces Analysis
5.6. Reimbursement Scenario by Key Countries
5.7. Pricing Analysis
5.8. Product/Brand Analysis
5.9. Epidemiology of Sickle Cell Disease
5.10. Technological Advancements
5.11. Supply Chain Analysis
5.12. Unmet Needs of the Market
6. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Antimetabolites
6.3.2. Amino Acids
6.3.3. NSAIDs
6.3.4. Monoclonal Antibodies
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Type, 2020-2034
7.3.1. Hemoglobin SS (HbSS)
7.3.2. Hemoglobin SC (HbSC)
7.3.3. Hemoglobin (HbS) beta thalassemia
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Age-Group
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Age-Group, 2020-2034
8.3.1. Children
8.3.2. Adults
8.4. Market Attractiveness Analysis, by Age-Group
9. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Route of Administration
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Route of Administration, 2020-2034
9.3.1. Oral
9.3.2. Parenteral
9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2020-2034
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020-2034
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Sickle Cell Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Antimetabolites
12.2.2. Amino Acids
12.2.3. NSAIDs
12.2.4. Monoclonal Antibodies
12.2.5. Others
12.3. Market Value Forecast, by Disease Type, 2020-2034
12.3.1. Hemoglobin SS (HbSS)
12.3.2. Hemoglobin SC (HbSC)
12.3.3. Hemoglobin (HbS) beta thalassemia
12.4. Market Value Forecast, by Age-Group, 2020-2034
12.4.1. Children
12.4.2. Adults
12.5. Market Value Forecast, by Route of Administration, 2020-2034
12.5.1. Oral
12.5.2. Parenteral
12.6. Market Value Forecast, by Distribution Channel, 2020-2034
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2020-2034
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Disease Type
12.8.3. By Age-Group
12.8.4. By Route of Administration
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Sickle Cell Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Antimetabolites
13.2.2. Amino Acids
13.2.3. NSAIDs
13.2.4. Monoclonal Antibodies
13.2.5. Others
13.3. Market Value Forecast, by Disease Type, 2020-2034
13.3.1. Hemoglobin SS (HbSS)
13.3.2. Hemoglobin SC (HbSC)
13.3.3. Hemoglobin (HbS) beta thalassemia
13.4. Market Value Forecast, by Age-Group, 2020-2034
13.4.1. Children
13.4.2. Adults
13.5. Market Value Forecast, by Route of Administration, 2020-2034
13.5.1. Oral
13.5.2. Parenteral
13.6. Market Value Forecast, by Distribution Channel, 2020-2034
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
13.7.1. Germany
13.7.2. UK
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Class
13.8.2. By Disease Type
13.8.3. By Age-Group
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Sickle Cell Disease Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Antimetabolites
14.2.2. Amino Acids
14.2.3. NSAIDs
14.2.4. Monoclonal Antibodies
14.2.5. Others
14.3. Market Value Forecast, by Disease Type, 2020-2034
14.3.1. Hemoglobin SS (HbSS)
14.3.2. Hemoglobin SC (HbSC)
14.3.3. Hemoglobin (HbS) beta thalassemia
14.4. Market Value Forecast, by Age-Group, 2020-2034
14.4.1. Children
14.4.2. Adults
14.5. Market Value Forecast, by Route of Administration, 2020-2034
14.5.1. Oral
14.5.2. Parenteral
14.6. Market Value Forecast, by Distribution Channel, 2020-2034
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Class
14.8.2. By Disease Type
14.8.3. By Age-Group
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Sickle Cell Disease Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Antimetabolites
15.2.2. Amino Acids
15.2.3. NSAIDs
15.2.4. Monoclonal Antibodies
15.2.5. Others
15.3. Market Value Forecast, by Disease Type, 2020-2034
15.3.1. Hemoglobin SS (HbSS)
15.3.2. Hemoglobin SC (HbSC)
15.3.3. Hemoglobin (HbS) beta thalassemia
15.4. Market Value Forecast, by Age-Group, 2020-2034
15.4.1. Children
15.4.2. Adults
15.5. Market Value Forecast, by Route of Administration, 2020-2034
15.5.1. Oral
15.5.2. Parenteral
15.6. Market Value Forecast, by Distribution Channel, 2020-2034
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2020-2034
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Class
15.8.2. By Disease Type
15.8.3. By Age-Group
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Sickle Cell Disease Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2020-2034
16.2.1. Antimetabolites
16.2.2. Amino Acids
16.2.3. NSAIDs
16.2.4. Monoclonal Antibodies
16.2.5. Others
16.3. Market Value Forecast, by Disease Type, 2020-2034
16.3.1. Hemoglobin SS (HbSS)
16.3.2. Hemoglobin SC (HbSC)
16.3.3. Hemoglobin (HbS) beta thalassemia
16.4. Market Value Forecast, by Age-Group, 2020-2034
16.4.1. Children
16.4.2. Adults
16.5. Market Value Forecast, by Route of Administration, 2020-2034
16.5.1. Oral
16.5.2. Parenteral
16.6. Market Value Forecast, by Distribution Channel, 2020-2034
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2020-2034
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Class
16.8.2. By Disease Type
16.8.3. By Age-Group
16.8.4. By Route of Administration
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Bristol-Myers Squibb Company
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Novartis AG
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Emmaus Medical, Inc.
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Bluebird bio Inc.
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Pfizer Inc.
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. CRISPR Therapeutics
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. F. Hoffmann-La Roche AG
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Vertex Pharmaceuticals Incorporated
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Agios Pharmaceuticals, Inc.
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. GlycoMimetics
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. Graphite Bio, Inc.
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
17.3.12. Mylan N.V.
17.3.12.1. Company Overview
17.3.12.2. Financial Overview
17.3.12.3. Product Portfolio
17.3.12.4. Business Strategies
17.3.12.5. Recent Developments
17.3.13. Teva Pharmaceutical Industries Ltd.
17.3.13.1. Company Overview
17.3.13.2. Financial Overview
17.3.13.3. Product Portfolio
17.3.13.4. Business Strategies
17.3.13.5. Recent Developments
17.3.14. AstraZeneca
17.3.14.1. Company Overview
17.3.14.2. Financial Overview
17.3.14.3. Product Portfolio
17.3.14.4. Business Strategies
17.3.14.5. Recent Developments
17.3.15. Hikma Pharmaceuticals PLC
17.3.15.1. Company Overview
17.3.15.2. Financial Overview
17.3.15.3. Product Portfolio
17.3.15.4. Business Strategies
17.3.15.5. Recent Developments
17.3.16. Addmedica
17.3.16.1. Company Overview
17.3.16.2. Financial Overview
17.3.16.3. Product Portfolio
17.3.16.4. Business Strategies
17.3.16.5. Recent Developments
List of Tables
Table 01: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
Table 02: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Disease Type, 2020-2034
Table 03: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Age-Group, 2020-2034
Table 04: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2034
Table 05: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2034
Table 06: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Region, 2020-2034
Table 07: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 08: North America Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
Table 09: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 10: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
Table 11: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 12: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Europe Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
Table 15: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 16: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
Table 17: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 18: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 19: Asia Pacific Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 20: Asia Pacific Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
Table 21: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 22: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
Table 23: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 24: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 25: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 26: Latin America Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
Table 27: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 28: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
Table 29: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 30: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 31: Middle East & Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 32: Middle East and Africa Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
Table 33: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 34: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
Table 35: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 36: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, 2020-2034
Figure 02: Global Sickle Cell Disease Treatment Market Value Share, by Drug Class, 2023
Figure 03: Global Sickle Cell Disease Treatment Market Value Share, by Disease Type, 2023
Figure 04: Global Sickle Cell Disease Treatment Market Value Share, by Age-Group, 2023
Figure 05: Global Sickle Cell Disease Treatment Market Value Share, by Route of Administration, 2023
Figure 06: Global Sickle Cell Disease Treatment Market Value Share, by End-user, 2023
Figure 07: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Drug Class, 2023 and 2034
Figure 08: Global Sickle Cell Disease Treatment Market Share Analysis, By Drug Class, 2023
Figure 09: Global Sickle Cell Disease Treatment Market Share Analysis, By Drug Class, 2034
Figure 10: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Class, 2024-2034
Figure 11: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Antimetabolites, 2020-2034
Figure 12: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Fixed Sickle Cell Disease Treatment, 2023 and 2034
Figure 13: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Amino Acids, 2020-2034
Figure 14: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Amino Acids, 2023 and 2034
Figure 15: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by NSAIDs, 2020-2034
Figure 16: Global Sickle Cell Disease Treatment Market Value Share Analysis, by NSAIDs, 2023 and 2034
Figure 17: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Monoclonal Antibodies, 2020-2034
Figure 18: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Monoclonal Antibodies, 2023 and 2034
Figure 19: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Others, 2020-2034
Figure 20: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Others, 2023 and 2034
Figure 21: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Disease Type, 2023 and 2034
Figure 22: Global Sickle Cell Disease Treatment Market Share Analysis, By Disease Type, 2023
Figure 23: Global Sickle Cell Disease Treatment Market Share Analysis, By Disease Type, 2034
Figure 24: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type, 2024-2034
Figure 25: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hemoglobin SS (HbSS), 2020-2034
Figure 26: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hemoglobin SS (HbSS), 2023 and 2034
Figure 27: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hemoglobin SC (HbSC) 2020-2034
Figure 28: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hemoglobin SC (HbSC), 2023 and 2034
Figure 29: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hemoglobin (HbS) beta thalassemia, 2020-2034
Figure 30: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hemoglobin (HbS) beta thalassemia, 2023 and 2034
Figure 31: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Age-Group, 2023 and 2034
Figure 32: Global Sickle Cell Disease Treatment Market Share Analysis, By Age-Group, 2023
Figure 33: Global Sickle Cell Disease Treatment Market Share Analysis, By Age-Group, 2034
Figure 34: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Age-Group, 2024-2034
Figure 35: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Children, 2020-2034
Figure 36: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Children, 2023 and 2034
Figure 37: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Adults, 2020-2034
Figure 38: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Adults, 2023 and 2034
Figure 39: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Route of Administration, 2023 and 2034
Figure 40: Global Sickle Cell Disease Treatment Market Share Analysis, By Route of Administration, 2023
Figure 41: Global Sickle Cell Disease Treatment Market Share Analysis, By Route of Administration, 2034
Figure 42: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Route of Administration, 2024-2034
Figure 43: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Oral, 2020-2034
Figure 44: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Oral, 2023 and 2034
Figure 45: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Parenteral, 2020-2034
Figure 46: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Parenteral, 2023 and 2034
Figure 47: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Distribution Channel, 2023 and 2034
Figure 48: Global Sickle Cell Disease Treatment Market Share Analysis, By Distribution Channel, 2023
Figure 49: Global Sickle Cell Disease Treatment Market Share Analysis, By Distribution Channel, 2034
Figure 50: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel, 2024-2034
Figure 51: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hospital Pharmacies, 2020-2034
Figure 52: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hospital Pharmacies, 2023 and 2034
Figure 53: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Retail Pharmacies, 2020-2034
Figure 54: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Retail Pharmacies, 2023 and 2034
Figure 55: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Online Pharmacies, 2020-2034
Figure 56: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Online Pharmacies, 2023 and 2034
Figure 57: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Region, 2023 and 2034
Figure 58: Global Sickle Cell Disease Treatment Market Share Analysis, by Region, 2023
Figure 59: Global Sickle Cell Disease Treatment Market Share Analysis, by Region, 2034
Figure 60: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, by Region, 2023-2034
Figure 61: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 62: North America - Sickle Cell Disease Treatment Market Value Share Analysis, by Country, 2023 and 2034
Figure 63: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country, 2024-2034
Figure 64: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 65: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 66: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 67: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 68: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
Figure 69: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
Figure 70: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 71: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 72: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 73: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 74: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 75: Europe - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 76: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 77: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 78: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 79: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 80: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 81: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
Figure 82: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
Figure 83: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 84: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 85: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 86: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 87: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 88: Asia Pacific - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 89: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 90: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 91: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 92: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 93: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 94: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
Figure 95: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
Figure 96: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 97: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 98: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 99: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 100: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 101: Latin America - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 102: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 103: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 104: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 105: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 106: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 107: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
Figure 108: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
Figure 109: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 110: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 111: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 112: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 113: Middle East & Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 114: Middle East & Africa - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 115: Middle East & Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 116: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 117: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 118: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 119: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 120: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
Figure 121: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
Figure 122: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 123: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 124: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 125: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Sickle Cell Disease Treatment Market
